SPECT/CT in differentiated thyroid carcinoma

Imaging in Medicine

Volumn 2, Issue 2, 2010, Pages 235-243

  Kuwert, Torsten ^a   Schmidt, Daniela ^b  

^a Clinic of Nuclear Medicine   (Germany)

^b NONE

Author keywords

CT; hybrid imaging; radioiodine; scintigraphy; SPECT; thyroid; thyroid cancer

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; RADIOISOTOPE; SODIUM IODIDE SYMPORTER;

COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DOSIMETRY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MECHANISM; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; REVIEW; SCINTIGRAPHY; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CARCINOMA;

EID: 77954136945     PISSN: 17555191     EISSN: 17555205     Source Type: Journal    
DOI: 10.2217/iim.10.11     Document Type: Review

References (52)

1. Schlumberger M Pacini F: Thyroid Tumors. Editions Nucléon Paris France (2003).
2. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W: European Thyroid Cancer Task Force: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154, 787-803 (2006).
3. Cooper DS, Doherty GM, Haugen BR et al.: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167-1214 (2009).
4. Santoro M, Carlomagno F: Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat. Clin. Pract. Endocrinol. Metab. 2, 42-52 (2006).
5. Weintraub BD, Szkudlinski MW: Development and in vitro characterization of human recombinant thyrotropin. Thyroid 9, 447-450, 1999.
6. Greene FI, Page LI, Fleming ID etal.: AJCC Cancer Staging Handbook. Springer, NY, USA (2002).
7. Dai G, Levy O, Carrasco N: Cloning and characterization of the thyroid iodide transporter. Nature 379, 458-460 (1996).
8. Castro MR, Bergert ER, Goellner JR, Hay ID, Morris JC: Immunohistochemical ana lysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J. Clin. Endocrinol. Metab. 86, 5627-5632 (2001).
9. 131I-iodide. J. Nucl. Med. 47, 1382-1388 (2006).
10. Maxon HR: Detection of residual and recurrent thyroid cancer by radionuclide imaging. Thyroid 9, 443-446 (1999).
11. Dong MJ, Liu ZF, Zhao K et al.: Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-ana lysis. Nucl. Med. Commun. 30, 639-650 (2009).
12. 18FDG-PET-CT Eur. Radiol. 19, 1425-1434 (2009).
13. 124I-PET/CT and FDG-PET Eur. J. Nucl. Med. Mol. Imaging35, 950-957 (2008).
14. 131I therapy Nucl. Med. Commun. 27, 165-169 (2006).
15. Hay ID, McDougall IR, Sisson JC: Perspective: the case against radioiodine remnant ablation in patients with well-differentiated thyroid carcinoma. J. Nucl. Med. 49, 1395-1397 (2008).
16. Verburg FA, Dietlein M, Lassmann M, Luster M, Reiners C: Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging36, 343-346 (2009).
17. 131I scans in patients with thyroid cancer. Semin. Nucl. Med. 30, 115-132 (2000).
18. Lind P, Kohlfürst S: Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin. Nucl. Med. 36, 194-205, 2006.
19. 131I whole-body scanning. J. Nucl. Med. 46, 1473-1480 (2005).
20. Caballero-Calabuig E, Cano-Terol C, Sopena-Monforte R et al.: Infuence of the thyroid remnant in the elevation of the serum thyroglobulin after thyroidectomy in differentiated thyroid carcinoma. Importance of the diagnostic iodine total-body scanning. Eur. J. Nucl. Med. Mol. Imaging 35, 1449-1456 (2008).
21. 131I SPECT and CT images in patients with differentiated thyroid carcinoma. J. Nucl. Med. 44, 1905-1910 (2003).
22. Seo Y, Mari C, Hasegawa BH: Technological development and advances in single-photon emission computed tomography/computed tomography Semin. Nucl. Med. 38, 177-198 (2008).
23. Patton JA, Townsend DW, Hutton BF: Hybrid imaging technology: from dreams and visions to clinical devices. Semin.-Nucl.-Med. 39, 247-263 (2009).
24. Even-Sapir E, Keidar Z, Bar-Shalom R: Hybrid imaging (SPECT/CT and PET/CT)-improving the diagnostic accuracy of functional/metabolic and anatomic imaging. Semin.-Nucl.-Med. 39, 264-275 (2009).
25. Bockisch A, Freudenberg LS, Schmidt D, Kuwert T: Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging. Semin.-Nucl.-Med.-39, 276-289 (2009).
26. Mariani G, Bruselli L, Kuwert T et-al.: A review on the clinical uses of SPECT/CT. Eur.-J.-Nucl.-Med.-Mol.-Imaging (2010) (In Press).
27. Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM: Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma. Br.-J.-Radiol. 82, 860-876 (2009).
28. 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur.-J.-Nucl.-Med.-Mol.-Imaging 31, 1435-1442 (2004).
29. Aide N, Lehembre E, Gervais R, Bardet S: Unusual intratracheal metastasis of differentiated thyroid cancer accurately depicted by SPECT/CT acquisition after radioiodine ablation. Thyroid 17, 1305-1306 (2007).
30. Macdonald W, Armstrong J: Benign struma ovarii in a patient with invasive papillary thyroid cancer: detection with I-131 SPECT-CT. Clin.-Nucl.-Med. 32, 380-382 (2007).
31. Rachinsky I, Driedger A: Iodine-131 uptake in a menstruating uterus: value of SPECT/CT in distinguishing benign and metastatic iodine-positive lesions. Thyroid 17, 901-902 (2007).
32. von Falck C, Beer G, Gratz KF, Galanski M: Renal metastases from follicular thyroid cancer on SPECT/CT. Clin.-Nucl.-Med. 32, 751-752 (2007).
33. Wong KK, Avram AM: Posttherapy I-131 thymic uptake demonstrated with SPECT/CT in a young girl with papillary thyroid carcinoma. Thyroid 18, 919-920 (2008).
34. Agriantonis DJ, Hall L, Wilson MA: Utility of SPECT/CT as an adjuct to planar whole body I-131 imaging: liver metastasis from papilary thyroid cancer. Clin.-Nucl.-Med. 34, 247-248 (2009).
35. Qiu Z, Luo Q: Erector spinae metastases from differentiated thyroid cancer identifed by I-131 SPECT/CT. Clin.-Nucl.-Med. 34, 137-140 (2009).
36. Thust S, Fernando R, Barwick T, Mohan H, Clarke SEM: SPECT/CT identifcation of post-radioactive iodine treatmet false-positive uptake in a simple renal cyst. Thyroid 19, 75-76 (2009).
37. Ruf J, Lehmkuhl L, Bertram H-et-al.: Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma. Nucl.-Med.-Commun. 25, 1177-1182 (2004).
38. 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. AJR-Am.-J.-Roentgenol.-191, 1785-1794 (2008).
39. 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma. J.-Nucl.-Med. 49, 1952-1957 (2008).
40. Wang H, Fu H-L, Li J-N, Zou R-J, Gu Z-H, Wu J-C: The role of single-photon emission computed tomography/computed tomography for precise localization of metastases in patients with differentiated thyroid cancer. Clin.-Imaging-33, 49-54 (2009).
41. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. J.-Nucl.-Med. 50, 184-190 (2009).
42. 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the frst radioablation. J. Nucl. Med. 50, 18-23 (2009).
43. 131I SPECT-CT offers high diagnostic accuracy when the fndings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen.Eur. J. Nucl. Med. Mol. Imaging 36, 886-893 (2009).
44. 131I scintigraphy for thyroid cancer. J. Clin. Endocrinol. Metab. 94, 2075-2084 (2009).
45. Mustafa M, Kuwert T, Weber K et al.: Regional lymph node involvement in T1 papillary thyroid carcinoma: a bicentric prospective SPECT/CT study. Eur. J. Nucl. Med. Mol. Imaging (2010) (In Press).
46. 131I SPECT/CT of the neck at the frst radioablation. Eur. J. Nucl. Med. Mol. Imaging (2009) (Epub ahead of print).
47. Schulz V, Nömayr A, Hornegger J etal.: Effect of CT-based attenuation correction on uptake ratios in skeletal SPECT Nuklearmedizin 46, 36-42 (2007).
48. Vandervoort E, Celler A, Harrop R: Implementation of an iterative scatter correction, the infuence of attenuation map quality and their effect on absolute quantitation in SPECT Phys. Med. Biol. 52, 1527-1545 (2007).
49. Shcherbinin S, Celler A, Belhocine T, Vanderwerf R, Driedger A: Accuracy of quantitative reconstructions in SPECT/CT imaging. Phys. Med. Biol. 53, 4595-4604 (2008).
50. Zeintl J, Vija AH, Yahil A, Hornegger J, Kuwert T: Quantitative accuracy of clinical Tc-99m SPECT/CT using OSEM with 3D resolution recovery, attenuation, and scatter correction. J. Nucl. Med. (2010) (In Press).
51. Song H, He B, Prideaux A et al.: Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J. Nucl. Med. 47, 1985-1994 (2006).
52. Sisson JC, Dewaraja YK, Wizauer EJ, Giordano TJ, Avram AM: Thyroid carcinoma metastasis to skull with infringement of the brain: treatment with radioiodine. Thyroid 19, 297-303 (2009).